These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23770199)

  • 1. Hepatocellular toxicity of clopidogrel: mechanisms and risk factors.
    Zahno A; Bouitbir J; Maseneni S; Lindinger PW; Brecht K; Krähenbühl S
    Free Radic Biol Med; 2013 Dec; 65():208-216. PubMed ID: 23770199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells.
    Zahno A; Brecht K; Morand R; Maseneni S; Török M; Lindinger PW; Krähenbühl S
    Biochem Pharmacol; 2011 Feb; 81(3):432-41. PubMed ID: 21070748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism and risk factors of clopidogrel-induced liver injury.
    Zhai Y; Wang L; Yang F; Feng G; Feng S; Cui T; An L; He X
    Drug Chem Toxicol; 2016 Oct; 39(4):367-74. PubMed ID: 26654298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites.
    Maseneni S; Donzelli M; Taegtmeyer AB; Brecht K; Krähenbühl S
    Toxicology; 2012 Sep; 299(2-3):139-45. PubMed ID: 22651985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of luteolin in primary rat hepatocytes: the role of CYP3A-mediated ortho-benzoquinone metabolite formation and glutathione depletion.
    Shi F; Zhao P; Li X; Pan H; Ma S; Ding L
    J Appl Toxicol; 2015 Nov; 35(11):1372-80. PubMed ID: 25612170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells.
    Jiang JZ; Yang BH; Ji LL; Yang L; Mao YC; Hu ZH; Wang ZT; Wang CH
    Toxicol In Vitro; 2017 Feb; 38():59-66. PubMed ID: 27836570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
    Abell LM; Liu EC
    J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
    Vinholt P; Poulsen TS; Korsholm L; Kristensen SR; Hallas J; Damkier P; Mickley H
    Thromb Haemost; 2005 Aug; 94(2):438-43. PubMed ID: 16113837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.
    Lau WC; Welch TD; Shields T; Rubenfire M; Tantry US; Gurbel PA
    J Cardiovasc Pharmacol; 2011 Jan; 57(1):86-93. PubMed ID: 20980920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
    Polena S; Gupta MP; Shaikh H; Zazzali K; Coplan N; Gintautas J; Labana SS; Soffer D
    Proc West Pharmacol Soc; 2008; 51():60-2. PubMed ID: 19544679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.
    Lau WC; Gurbel PA; Watkins PB; Neer CJ; Hopp AS; Carville DG; Guyer KE; Tait AR; Bates ER
    Circulation; 2004 Jan; 109(2):166-71. PubMed ID: 14707025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
    Ford NF
    J Clin Pharmacol; 2016 Dec; 56(12):1474-1483. PubMed ID: 27196064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Danshen capsules on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Zhou CH; Xu M; Yu HB; Zheng XT; Zhong ZF; Zhang LT
    Food Chem Toxicol; 2018 Sep; 119():302-308. PubMed ID: 29496531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
    Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity.
    Wu Q; Ning B; Xuan J; Ren Z; Guo L; Bryant MS
    Toxicol Lett; 2016 Jun; 253():55-62. PubMed ID: 27113703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
    Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
    Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.
    Tirkkonen T; Heikkilä P; Vahlberg T; Huupponen R; Laine K
    Cardiovasc Ther; 2013 Dec; 31(6):344-51. PubMed ID: 23773422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
    Brophy JM; Babapulle MN; Costa V; Rinfret S
    Am Heart J; 2006 Aug; 152(2):263-9. PubMed ID: 16875906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.